{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:08:49Z","timestamp":1790179729650,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jgar.2026.07.017","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T15:22:35Z","timestamp":1784906555000},"page":"334-342","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Three-year outcomes after genotyping-guided treatment switch in HIV patients with virologic failure in Cameroon: Implications for epidemic control in low- and middle-income countries"],"prefix":"10.1016","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8768-2371","authenticated-orcid":false,"given":"Ezechiel Ngoufack Jagni","family":"Semengue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chanelle Magnilack","family":"Kuete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6336-6160","authenticated-orcid":false,"given":"Abdel Jelil","family":"Njouendou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Collins Ambe","family":"Chenwi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dell-Dylan","family":"Kenfack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent Kama\u00ebl","family":"Mekel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph Matute","family":"Njako","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella Diabe","family":"Munge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ladifatou","family":"Supuen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Berinyuy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Synthia Njuzy","family":"Eduke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela Patricia","family":"Tueguem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e9sir\u00e9","family":"Takou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gr\u00e2ce Beloumou","family":"Angong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine Claire Djupsa","family":"Ndjeyep","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex Durand","family":"Nka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aude","family":"Christelle Ka\u2019e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi-Karell","family":"Etame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evariste","family":"Molimbou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana Anim-Keng","family":"Tekoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0916-0142","authenticated-orcid":false,"given":"Derrick Tambe Ayuk","family":"Ngwese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa Gaelle Moko","family":"Fotso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Cecile Z-K","family":"Bissek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo-Federico","family":"Perno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicaise","family":"Ndembi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Fokam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Ndjolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2026.07.017_bib0001","unstructured":"World Health Organization, \u201cWHO HIVResNet HIV drug resistance laboratory operational framework,\u201d World health organization. [accessed 08.01.24]. https:\/\/www.who.int\/publications-detail-redirect\/978-92-4-000987-5."},{"key":"10.1016\/j.jgar.2026.07.017_bib0002","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJMoa1507198","article-title":"A trial of early antiretrovirals and isoniazid preventive therapy in Africa","volume":"373","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgar.2026.07.017_bib0003","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0048726","article-title":"The determinants of HIV treatment costs in resource-limited settings","volume":"7","author":"Menzies","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jgar.2026.07.017_bib0004","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1093\/infdis\/jix089","article-title":"Impact of HIV drug resistance on HIV\/AIDS-associated mortality, new infections, and antiretroviral therapy program costs in sub-Saharan Africa","volume":"215","author":"Phillips","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jgar.2026.07.017_bib0005","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1093\/jac\/dkaa178","article-title":"In vitro susceptibility to fostemsavir is not affected by long-term exposure to antiviral therapy in MDR HIV-1-infected patients","volume":"75","author":"Saladini","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2026.07.017_bib0006","unstructured":"World Health Organization, \u201cHIV drug resistance report 2021.\u201d [accessed 19.08.25]: https:\/\/www.who.int\/publications\/i\/item\/9789240038608."},{"key":"10.1016\/j.jgar.2026.07.017_bib0007","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.3390\/v15071458","article-title":"Pre-treatment HIV drug resistance and genetic diversity in Cameroon: implications for first-line regimens","volume":"15","author":"Fokam","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.jgar.2026.07.017_bib0008","unstructured":"World Health Organization, \u201cHIV data and statistics.\u201d [accessed 19.08.25]: https:\/\/www.who.int\/teams\/global-hiv-hepatitis-and-stis-programmes\/hiv\/strategic-information\/hiv-data-and-statistics."},{"key":"10.1016\/j.jgar.2026.07.017_bib0009","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1093\/jac\/dkab406","article-title":"Prevalence and patterns of HIV drug resistance in patients with suspected virological failure in north-western Tanzania","volume":"77","author":"Henerico","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2026.07.017_bib0010","unstructured":"National Institutes of Health, \u201cDrug resistance,\u201d HIVinfo.NIH.gov. [accessed 02.07.24]: https:\/\/hivinfo.nih.gov\/understanding-hiv\/fact-sheets\/drug-resistance."},{"key":"10.1016\/j.jgar.2026.07.017_bib0011","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000033897","article-title":"HIV-1 genotypic profiling ensures effective response to third-line antiretroviral therapy in Cameroon","volume":"102","author":"Mbouyap","year":"2023","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jgar.2026.07.017_bib0012","unstructured":"National Institutes of Health, \u201cDrug-Resistance testing and use of drug-resistance assays.\u201d [accessed 02.07.24]: https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/hiv-clinical-guidelines-adult-and-adolescent-arv\/drug-resistance-testing-and-use-drug."},{"key":"10.1016\/j.jgar.2026.07.017_bib0013","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1472-6963-14-116","article-title":"Implementing antiretroviral resistance testing in a primary health care HIV treatment programme in rural KwaZulu-Natal, South Africa: early experiences, achievements and challenges","volume":"14","author":"Lessells","year":"2014","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.jgar.2026.07.017_bib0014","first-page":"2612","article-title":"Genotypic resistance testing improves antiretroviral treatment outcomes in a cohort of adolescents in Cameroon: implications in the dolutegravir era","volume":"14","author":"Togna Pabo","year":"2023","journal-title":"J Public Health Afr"},{"key":"10.1016\/j.jgar.2026.07.017_bib0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0236642","article-title":"Survival among antiretroviral-experienced HIV-2 patients experiencing virologic failure with drug resistance mutations in Cote d\u2019Ivoire, West Africa","volume":"15","author":"Tchounga","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.jgar.2026.07.017_bib0016","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jgar.2022.07.022","article-title":"Virological efficacy of switch to DTG plus 3TC in a retrospective observational cohort of suppressed HIV-1 patients with or without past M184V: the LAMRES study","volume":"31","author":"Santoro","year":"2022","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.jgar.2026.07.017_bib0017","doi-asserted-by":"crossref","first-page":"e267","DOI":"10.1016\/S1473-3099(16)30118-9","article-title":"Affordable HIV drug-resistance testing for monitoring of antiretroviral therapy in sub-Saharan Africa","volume":"16","author":"Inzaule","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jgar.2026.07.017_bib0018","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S1473-3099(09)70136-7","article-title":"Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis","volume":"9","author":"Gupta","year":"2009","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jgar.2026.07.017_bib0019","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.meegid.2016.08.031","article-title":"HIV-1 drug resistance and resistance testing","volume":"46","author":"Clutter","year":"2016","journal-title":"Infect Genet Evol"},{"key":"10.1016\/j.jgar.2026.07.017_bib0020","unstructured":"World Health Organization, \u201cWorld Health Organization African Region_The Centre International de R\u00e9f\u00e9rence Chantal BIYA designated WHO HIVResNet national HIV drug resistance (HIVDR) testing laboratory.\u201d [accessed 13.09.25]: https:\/\/www.facebook.com\/WHOAFRO\/posts\/the-centre-international-de-r%C3%A9f%C3%A9rence-chantal-biya-circb-in-cameroon-a-national-\/1050926180547768\/."},{"key":"10.1016\/j.jgar.2026.07.017_bib0021","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1007\/s00705-011-0982-3","article-title":"Performance evaluation of an in-house human immunodeficiency virus type-1 protease-reverse transcriptase genotyping assay in Cameroon","volume":"156","author":"Fokam","year":"2011","journal-title":"Arch Virol"},{"key":"10.1016\/j.jgar.2026.07.017_bib0022","first-page":"1936","article-title":"Automating HIV drug resistance genotyping with RECall, a freely accessible sequence analysis tool","author":"Woods","year":"201250","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jgar.2026.07.017_bib0023","unstructured":"Abbott, \u201cAbbott GmbH & Co. KG - Wiesbaden, Germany,\u201d Abbott. [accessed 13.09.25]: https:\/\/www.bionity.com\/en\/companies\/18049\/abbott-gmbh-co-kg.html."},{"key":"10.1016\/j.jgar.2026.07.017_bib0024","unstructured":"World Health Organization, \u201cWHAT\u2019S new in treatment MONITORING: viral load and CD4 testing,\u201d 2017, [accessed 29.05.24] https:\/\/iris.who.int\/bitstream\/handle\/10665\/255891\/WHO-HIV-2017.22-eng.pdf."},{"key":"10.1016\/j.jgar.2026.07.017_bib0025","unstructured":"Ministry of Public Health Cameroon, \u201cNATIONAL guidelines for hiv\/aids prevention and management in cameroon 2024,\u201d 2024. [accessed 13.09.25] https:\/\/www.cnls.cm\/uploads\/docs\/2025-04-29-hiv-prevention-and-care-guidelines-2024-final-28042025-validee.pdf."},{"key":"10.1016\/j.jgar.2026.07.017_bib0026","doi-asserted-by":"crossref","first-page":"103896","DOI":"10.1016\/j.ebiom.2022.103896","article-title":"Ageing with HIV: challenges and biomarkers","volume":"77","author":"Rod\u00e9s","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jgar.2026.07.017_bib0027","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1016\/S2666-7568(21)00278-6","article-title":"Biological ageing with HIV infection: evaluating the geroscience hypothesis","volume":"3","author":"Montano","year":"2022","journal-title":"Lancet Healthy Longev"},{"key":"10.1016\/j.jgar.2026.07.017_bib0028","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0235958","article-title":"Pre-treatment drug resistance and HIV-1 genetic diversity in the rural and urban settings of Northwest Cameroon","volume":"15","author":"Fokam","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.jgar.2026.07.017_bib0029","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.puhe.2020.01.014","article-title":"The effect of gender inequality on HIV incidence in sub-Saharan Africa","volume":"182","author":"Sia","year":"2020","journal-title":"Public Health"},{"key":"10.1016\/j.jgar.2026.07.017_bib0030","doi-asserted-by":"crossref","first-page":"e2540","DOI":"10.1002\/rmv.2540","article-title":"Prevalence and factors associated with viral non-suppression in people living with HIV receiving antiretroviral therapy in sub-Saharan Africa: a systematic review and meta-analysis","volume":"34","author":"Mosha","year":"2024","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.jgar.2026.07.017_bib0031","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1186\/s12879-019-3871-0","article-title":"HIV-1 drug resistance testing is essential for heavily treated patients switching from first- to second-line regimens in resource-limited settings: evidence from routine clinical practice in Cameroon","volume":"19","author":"Takou","year":"2019","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jgar.2026.07.017_bib0032","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.25157","article-title":"Development of HIV drug-resistance mutations and antiretroviral efficacy among Vietnamese patients after failure of 5-year first-line therapy","volume":"39","author":"Hung","year":"2025","journal-title":"J Clin Lab Anal"},{"key":"10.1016\/j.jgar.2026.07.017_bib0033","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1093\/cid\/ciad177","article-title":"Contribution of low CD4 cell counts and high human immunodeficiency virus (HIV) viral load to the efficacy of preferred first-line antiretroviral regimens for treating HIV infection: a systematic review and meta-analysis","volume":"76","author":"Perez-Molina","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2026.07.017_bib0034","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0293326","article-title":"HIV-1 subtype diversity and immuno-virological outcomes among adolescents failing antiretroviral therapy in Cameroon: a cohort study","volume":"18","author":"Togna Pabo","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.jgar.2026.07.017_bib0035","article-title":"Approaches to the management of virologic failure on dolutegravir-based antiretroviral therapy in the 50 countries with the highest adult HIV prevalence","author":"Nutt","year":"2025","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2026.07.017_bib0036","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/hiv.13062","article-title":"Virological response and resistance profile in highly treatment-experienced HIV-1-infected patients switching to dolutegravir plus boosted darunavir in clinical practice","volume":"22","author":"Armenia","year":"2021","journal-title":"HIV Med"},{"key":"10.1016\/j.jgar.2026.07.017_bib0037","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1089\/apc.2019.0198","article-title":"Virological outcome after choice of antiretroviral regimen guided by proviral HIV-1 DNA genotyping in a real-life cohort of HIV-infected patients","volume":"34","author":"Meybeck","year":"2020","journal-title":"AIDS Patient Care STDS"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716526001219?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716526001219?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T15:53:34Z","timestamp":1790178814000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716526001219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":37,"alternative-id":["S2213716526001219"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2026.07.017","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Three-year outcomes after genotyping-guided treatment switch in HIV patients with virologic failure in Cameroon: Implications for epidemic control in low- and middle-income countries","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2026.07.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}